A urology expert elucidates the collaborative relationship between medical oncology and urology in terms of diagnostic testing, treatment strategies, and patient referrals, while underscoring the crucial role of a multidisciplinary approach in maximizing positive patient outcomes.
A key opinion leader presents a case study of a 73-year-old male patient diagnosed with metastatic urothelial carcinoma, highlighting the associated risk factors and challenges in establishing an accurate diagnosis.
Breast cancer specialists review key efficacy and safety data from the DESTINY-Breast04 trial investigating trastuzumab deruxtecan in patients with HR+/HER2-low metastatic breast cancer.
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, discuss treatment sequencing practices and ongoing challenges in patients with HR+/HER2-low breast cancer.
Toni Choueiri, MD, and the Oncology Brothers discuss the PSMAfore study evaluating health-related quality of life and pain in taxane-naïve patients with metastatic castration-resistant prostate cancer.
Medical oncologists discuss how real-world evidence from the IMDC is informing treatment decisions in GU cancer.
Focusing on renal cell carcinoma, the Oncology Brothers and Toni Choueiri, MD, discuss KIM-1, a biomarker analysis in IMmotion010.
Toni Choueiri, MD, and the Oncology Brothers discuss the role of circulating tumor DNA in treatment paradigms for patients with genitourinary cancers.
Following ASCO 2024, Toni Choueiri, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss recent updates from the EV-302 study investigating enfortumab vedotin plus pembrolizumab in metastatic urothelial carcinoma.
Christopher Moertel, MD, discusses mirdametinib's mechanism of action and the implications of the phase 2b ReNeu trial of the agent in NF1-associated plexiform neurofibroma.
Michael Serzan, MD, discusses what a community oncologist should know about the phase 2 ARCITECT trial for patients with clear cell renal cell carcinoma.
Vitaly Margulis, MD, discusses the significance of a 100% biochemical recurrence-free rate at 2 years, and what this means for patients with high-risk localized prostate cancer.
Vitaly Margulis, MD, discusses the Apa-RP study of adjuvant treatment consisting of apalutamide and androgen deprivation therapy in patients with high-risk localized prostate cancer.
Jay Spiegel, MD, discusses what led to the initiation of a phase 2 study evaluating CRG-022 in patients with relapsed/refractory large B-cell lymphoma following treatment with CD19-directed CAR T-cell therapy.
Bradley McGregor, MD, discusses how ongoing trials hold the key for further breakthroughs in genitourinary cancer treatment.
Paolo Ghia, MD, PhD, discusses safety and efficacy findings from a 5-year update of the phase 2 CAPTIVATE trial for chronic lymphocytic leukemia and/or small lymphocytic lymphoma treatment.
Focusing on HER2+ breast cancer, Erika P. Hamilton, MD, and the Oncology Brothers review data from JBCRG-M06/EMERALD looking at trastuzumab and pertuzumab in combination with eribulin or a taxane in locally advanced or metastatic disease.
Erika P. Hamilton, MD, and the Oncology Brothers review exciting data from DESTINY-Breast06 and discuss its impact on the evolving treatment landscape.
Medical oncologists discuss the INAVO120 study, which is evaluating inavolisib combination therapy in patients with PIK3CA-mutated breast cancer.
The Oncology Brothers and Erika P. Hamilton, MD, discuss the postMONARCH study investigating fulvestrant alone vs fulvestrant plus abemaciclib.
Following ASCO 2024, Erika P. Hamilton, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to review recent updates from the RxPONDER trial investigating the use of AMH levels in premenopausal women.
Mark A. Lewis, MD, discusses the exciting progress of dostarlimab in treating rectal cancer.
Bradley McGregor, MD, discusses background of the DAD trial evaluating sacituzumab govitecan-hziy in combination with enfortumab vedotin-ejfv for the treatment of patients with treatment-resistant metastatic urothelial carcinoma.
Dr. Bose provides guidance on how he would approach ruxolitinib dosing if the patient's platelet count was 150 at week 12, including the potential use of the 5 mg tablet.
Dr. Bose discusses the REALISE trial and its implications for ruxolitinib dosing strategy, particularly in terms of safety and efficacy, and the purpose of this dosing strategy assessment in this patient population.
Dr. Bose shares his experience in managing anemia in patients with myelofibrosis, including current strategies used in his practice and the effect of the degree of anemia on treatment approach.
Dr. Bose discusses the impact of ruxolitinib on the overall survival of patients with MF and briefly reviews the COMFORT I and COMFORT II trials that led to the approval of ruxolitinib.
Dr. Bose explains the treatment goals for patients with MF, including the role of overall survival (OS) as a treatment goal.
Dr. Bose discusses the key diagnostic findings that support the diagnosis of myelofibrosis (MF) in this patient and reviews the treatment options and selection in accordance with the treatment guidelines for MF.
Dr. Bose reviews the case of a 68-year-old woman with myelofibrosis presenting with mild fatigue, anemia, splenomegaly, and intermediate-2/high risk disease based on prognostic scoring systems.